. Author manuscript; available in PMC: 2018 Oct 5.

Published in final edited form as: N Engl J Med. 2018 Mar 21;378(14):1277–1290. doi: 10.1056/NEJMoa1712126

Table 2.

Antitumor Activity in IMDC Intermediate- and Poor-Risk Patients.^*

Variable	Nivolumab plus Ipilimumab (N = 425)	Sunitinib (N = 422)

Confirmed objective response rate — % (95% CI)^†	42 (37-47)^‡	27 (22-31)^‡

Confirmed best overall response — no. (%)^†

Complete response	40 (9)^‡^§	5 (1)^‡^§

Partial response	137 (32)	107 (25)

Stable disease	133 (31)	188 (45)

Progressive disease	83 (20)	72 (17)

Unable to determine or not reported	32 (8)	50 (12)

Median time to response (range) — mo	2.8 (0.9-11.3)	3.0 (0.6-15.0)

Median duration of response (95% CI) — mo	NR (21.8-NE)	18.2 (14.8-NE)

Patients with ongoing response — no./total no. (%)	128/177 (72)	71/112 (63)

NE denotes not estimable, and NR not reached.

^†

Response was assessed according to Response Evaluation Criteria in Solid Tumors, version 1.1, by an independent radiology review committee.

^‡

P<0.001 for the difference between groups.

^§

The analysis of the between-group difference in complete response was exploratory.